Nature reviews. Clinical oncology 2024 Dec
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
Related Questions
The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anapla...
New answer by Radiation Oncologist at Florida International University (February 26, 2025)
INDIGO has stirred up the blues, as can clearly be seen by the responses here. The issues raised are extremely valid and rather than rehash the critical points already brought...